Review
Immunology
Ya-Jui Lin, Caren Yu-Ju Wu, Janet Yuling Wu, Michael Lim
Summary: Glioblastoma is a highly aggressive glioma with resistance to immunotherapy, primarily due to the unique immune environment. Myeloid cells play a significant role in the glioma microenvironment and reprogramming them has emerged as a revolutionary immunotherapy for glioma treatment. This article provides a detailed classification and analysis of myeloid cells in glioma TME, aiming to offer new insights and therapeutic approaches for improving treatment efficacy in glioma patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Ye Zheng, Xiaoyu Ma, Shouchang Feng, Hongtao Zhu, Xin Chen, Xingjiang Yu, Kai Shu, Suojun Zhang
Summary: Glioblastoma (GBM), the most malignant subtype of glioma, is resistant to traditional therapies and immunotherapies. Dendritic cell vaccine (DCV) has shown potential as a therapeutic method, but there are challenges to its use.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Claire A. Conarroe, Timothy N. J. Bullock
Summary: High-grade gliomas are malignant brain tumors, and despite the use of immunotherapies, patient outcomes remain poor. Dendritic cells (DC) play a crucial role in initiating an immune response against tumors, but research on their activity in high-grade gliomas is lacking. This review discusses the role of DC in the central nervous system, their infiltration in high-grade gliomas, antigen presentation, immunogenicity, and subsets involved in the antitumor immune response. It also explores the implications of suboptimal DC function in immunotherapies and opportunities for optimization in treating high-grade gliomas.
Article
Neurosciences
Shan Cheng, Liang Liu, Delin Wang, Yongdong Li, Suwen Li, Jiaqi Yuan, Shilu Huang, Zhipeng Xu, Bin Jia, Zhe Li, Jun Dong
Summary: This study revealed that transformed dendritic cells (t-DCs) maintained some dendritic cell-specific surface markers and exhibited decreased expression of immune-related costimulatory molecules under immunosuppressive conditions mediated by glioma stem cells (GSCs). The expression of PTX3 and its transcription factor ZNF148 was upregulated in t-DCs, promoting their proliferation and migration. The ZNF148/PTX3 axis may play a crucial role in regulating the malignant transformation of dendritic cells.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Oncology
Zining Wang, Feifei Xu, Jie Hu, Hongxia Zhang, Lei Cui, Wenhua Lu, Wenzhuo He, Xiaojuan Wang, Mengyun Li, Huanling Zhang, Wenjing Xiong, Chunyuan Xie, Yongxiang Liu, Penghui Zhou, Jinyun Liu, Peng Huang, Xiaofeng Frank Qin, Xiaojun Xia
Summary: Clotrimazole was identified as a drug that could enhance DC-mediated antigen presentation and T cell response, by acting on hexokinase 2 to regulate metabolic production and enhancing the lysosome pathway and Chop expression in DCs. In vivo administration of clotrimazole induced immune infiltration and inhibited tumor growth, synergizing with anti-PD1 antibody therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Cell Biology
Hongtao Zhu, Xingjiang Yu, Suojun Zhang, Kai Shu
Summary: The complement system plays a significant role in the development of malignant glioma and may serve as potential therapeutic targets and prognostic factors. Specifically targeting the complement system could be of great significance in future treatments for various types of tumors.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Medicine, Research & Experimental
Xiangling Zhu, Yilong Fang, Yizhao Chen, Yu Chen, Wenming Hong, Wei Wei, Jiajie Tu
Summary: Glioma, the most common primary central nervous system tumor, is closely associated with glioma stem cells (GSCs). Despite the improved therapeutic outcome of glioma with the use of temozolomide, resistance is still present in many patients. Additionally, the interaction between GSCs and tumor-associated microglia/macrophages (TAMs) has been found to impact the occurrence, growth, and response to chemoradiotherapy in glioma. This study highlights the crucial roles of GSCs in maintaining their stemness and recruiting TAMs to the tumor microenvironment, leading to their polarization into tumor-promoting macrophages, thereby providing a foundation for future research on new cancer treatment strategies.
Article
Oncology
Xiaowu Bai, Chi Chun Wong, Yasi Pan, Huarong Chen, Weixin Liu, Jianning Zhai, Wei Kang, Yu Shi, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Philip Chiu, Jun Yu, Enders Kwok-wai Ng
Summary: YTHDF1 is overexpressed in gastric cancer and promotes cancer growth by inducing cell proliferation and suppressing dendritic cell-mediated anti-tumor immune response. YTHDF1 is a promising therapeutic target for gastric cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Pharmacology & Pharmacy
Qin-Xuan Xia, Jing Yu, Zhao-Jun Wang, Qi-Wen Guan, Xiao-Yuan Mao
Summary: This study demonstrates that LOXs have significant predictive value for prognosis, chemotherapy, and immunotherapy in glioma patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Jingjing Wu, Ranran Zhu, Zhengxia Wang, Xueqin Chen, Tingting Xu, Yanan Liu, Meijuan Song, Jingxian Jiang, Qiyun Ma, Zhongqi Chen, Yuan Liu, Xiaoyue Wang, Mingshun Zhang, Mao Huang, Ningfei Ji
Summary: CD3(+)CD4(-)CD8(-) double-negative T (DNT) cells are increased in malignant pleural effusions (MPEs) from lung cancer patients. These DNT cells express high levels of PD-1 and TRAIL, and their cytotoxicity is impaired by exosomes derived from MPEs.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Immunology
Kiwan Kim, Ho-Shin Gwak, Nayoung Han, Eun Kyung Hong, Beom K. Choi, Sangeun Lee, Soyoung Choi, Ju-Hwang Park, Ji-Hye Seok, Yeongha Jeon, Hyuntae Cho, Song-Jae Lee, Yura Lee, Ki Taek Nam, Seong-Won Song
Summary: This study demonstrates the efficacy of IL13R alpha 2-targeted YYB-103 CAR T cells against MG cells. The modification of IL13 to construct a CAR enabled the selective targeting of IL13R alpha 2-expressing MG cells while sparing IL13R alpha 1-expressing cells. Additionally, YYB-103 CAR T cells showed effective blood-brain barrier crossing, suggesting compatibility with intravenous administration.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Min Chen, Kaixiang Zhou, Sheng-Yao Dai, Sirimuvva Tadepalli, Preethi Bala Balakrishnan, Jinghang Xie, Fadi E. I. Rami, Tingting Dai, Liyang Cui, Juliana Idoyaga, Jianghong Rao
Summary: This study presents a bioluminescence probe, GBLI-2, for real-time imaging of granzyme B activity in tumors undergoing immune checkpoint inhibitor therapy. The GBLI-2 signal correlated with changes in the population of PD-1 and granzyme B-expressing CD8+ T cells in tumors.
CELL CHEMICAL BIOLOGY
(2022)
Article
Oncology
Yuanfan Yang, Michael C. Brown, Gao Zhang, Kevin Stevenson, Malte Mohme, Reb Kornahrens, Darell D. Bigner, David M. Ashley, Giselle Y. Lopez, Matthias Gromeier
Summary: In malignant gliomas, GAMM contribute to immune suppression and tumor progression through CD155 upregulation. Treatment with PVSRIPO activates GAMM and leads to tumor regression without directly infecting malignant cells. Combination therapy of PVSRIPO and PD1/PD-L1 blockade results in durable remissions.
Review
Oncology
Xiaoyu Ma, Hongtao Zhu, Lidong Cheng, Xin Chen, Kai Shu, Suojun Zhang
Summary: This review discusses the role of FGL2 in glioblastoma (GBM) and its potential as a target for immunotherapy. FGL2 plays an immunosuppressive role in the GBM tumor microenvironment and promotes malignant tumor progression. Understanding the role of FGL2 in GBM can improve immunotherapy efficacy and treatment protocols.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Qiankun Ji, Zewei Tu, Junzhe Liu, Kai Huang, Xingen Zhu, Jingying Li
Summary: Through analysis of metabolic genes (MEGs), this study identified four metabolic-associated subtypes with different clinical characteristics and established a robust scoring system with significant clinical application value. In addition, a potential therapeutic target for glioma -- tumor suppressor gene ATP1A3 was discovered, which is of great significance in the diagnosis, prognosis, and prediction of the response to immune checkpoint blockers (ICBs) for glioma patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Elin Pauwels, Frederik Cleeren, Terence Tshibangu, Michel Koole, Kim Serdons, Lennert Boeckxstaens, Jeroen Dekervel, Timon Vandamme, Willem Lybaert, Bliede Van den Broeck, Annouschka Laenen, Paul M. Clement, Karen Geboes, Eric Van Cutsem, Sigrid Stroobants, Chris Verslype, Guy Bormans, Christophe M. Deroose
Summary: A recent multicenter trial demonstrated that 18F-AlF-OC, as a radiotracer, is noninferior to 68Ga-DOTA-SSA in somatostatin receptor imaging for neuroendocrine tumor patients. This study provides scientific evidence for the clinical application of 18F-AlF-OC.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Oncology
Vibeke K. J. Vergote, Gregor Verhoef, Ann Janssens, F. J. Sherida H. Woei-A-Jin, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe M. Deroose
Summary: Multiple studies have demonstrated the predictive value of pretreatment [F-18]FDG-PET/CT metabolic parameters in various lymphoma subtypes. However, there is limited research on the role of metabolic parameters in mantle cell lymphoma (MCL). In this retrospective study, we investigated the prognostic value of baseline metabolic tumor volume (MTV) and lesion dissemination in untreated MCL. We found that higher baseline MTV was associated with worse overall survival, progression-free survival, and disease-specific survival in univariate analysis. Furthermore, MTV was significantly associated with disease-specific survival in multivariate analysis. However, there was no correlation between lesion dissemination and outcome. Overall, these findings suggest that MTV is an important prognostic tool and can improve risk stratification for untreated MCL at staging.
LEUKEMIA & LYMPHOMA
(2023)
Review
Virology
Eline Pellaers, Anayat Bhat, Frauke Christ, Zeger Debyser
Summary: To complete replication, retroviruses integrate their RNA genome into a host chromosome by selecting specific integration sites. These integration sites play important roles in retroviral replication, oncogenesis, and latency. This review summarizes the mechanisms underlying integration site selection in gammaretrovirus MLV and lentivirus HIV-1 and discusses how understanding these mechanisms can contribute to the development of safer viral vectors for gene therapy and potentially lead to a cure for HIV-1 infection.
Article
Cardiac & Cardiovascular Systems
Lauranne Van Assche, Bart Peeters, Anne Vorlat, Koen Monsieurs, Hein Heidbuchel, Marc J. Claeys
Summary: This study evaluates the safety and effectiveness of the 0-1h hs-cTn algorithm compared to the standard 0-3h cTn protocol for diagnosing AMI. The results show that the 0-1h hs-cTn protocol has a sensitivity of 100% and a negative predictive value of 100% for ruling out AMI.
Article
Clinical Neurology
Diego Cabezudo, George Tsafaras, Eva Van Acker, Chris Van den Haute, Veerle Baekelandt
Summary: This study provides evidence for the central role of LRRK2 protein in gut inflammation and Parkinson's disease. The G2019S mutation in LRRK2 increases inflammatory response and disease phenotype. The study also shows that gut inflammation can impact brain homeostasis and contribute to neurodegeneration in Parkinson's disease.
ACTA NEUROPATHOLOGICA
(2023)
Article
Oncology
Lize Vanaken, F. J. Sherida H. Woei-A-Jin, Rita Van Ginderdeuren, Christophe M. Deroose, Annouschka Laenen, Guy Missotten, Dietmar R. Thal, Oliver Bechter, Patrick Schoffski, Paul Clement
Summary: This study aimed to investigate the efficacy of immune checkpoint inhibitors (ICI) in patients with metastatic uveal melanoma (MUM). The results showed that ICI did not improve overall survival in MUM patients. Local treatment options may be more beneficial compared to ICI.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Eef Vanerwegen, Niloefar Ahmadi Bidakhvidi, Vibeke K. J. Vergote, Ann Janssens, Christophe M. Deroose
Summary: Malignancy-associated cerebellar hypermetabolism on [F-18]FDG PET/CT can be caused by paraneoplastic autoimmune encephalitis or neoplasias, such as leptomeningeal/cerebellar metastases or primary cerebellar tumors. We present a case of a 33-year-old man with newly diagnosed Hodgkin lymphoma, who unexpectedly showed intense cerebellar hypermetabolism on his staging [F-18]FDG PET/CT despite having only episodic headaches. Neurolymphomatosis and paraneoplastic subacute cerebellar degeneration were ruled out, and cerebrospinal fluid analysis revealed Cryptococcus neoformans meningitis, suggesting that central nervous system infections should also be considered as a differential diagnosis in malignancy-related cerebellar hypermetabolism.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lennert Boeckxstaens, Elin Pauwels, Vincent Vandecaveye, Wies Deckers, Frederik Cleeren, Jeroen Dekervel, Timon Vandamme, Kim Serdons, Michel Koole, Guy Bormans, Annouschka Laenen, Paul M. Clement, Karen Geboes, Eric Van Cutsem, Kristiaan Nackaerts, Sigrid Stroobants, Chris Verslype, Koen Van Laere, Christophe M. Deroose
Summary: Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients. We demonstrated the superiority of [F-18]AlF-OC PET/CT over [Ga-68]Ga-DOTA-SSA in clinical performance. MRI analysis confirmed that the majority of [F-18]AlF-OC PET lesions are true NET lesions.
Article
Immunology
Glynis Frans, Doreen Dillaerts, Tom Dehaemers, Jan Van Elslande, Jonas De Leeuw, Lise Boon, Wim Maes, Nico Callewaert, Bas Calcoen, Lina Ancheva, Maaike Cockx, Nick Geukens, Kusay Arat, Rita Derua, Pieter Vermeersch, Sebastien Christian Carpentier, Xavier Bossuyt
Summary: Pre-vaccination SARS-CoV-2 infection enhances vaccine-induced protection, while post-vaccination breakthrough infections boost existing immunity. The resulting 'hybrid immunity' is effective against SARS-CoV-2 variants. Molecular analysis of the complementarity determining regions (CDR) of antibodies from individuals with hybrid immunity and vaccinated individuals without infection reveals distinct CDR profiles.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Wyanne A. Noortman, Nicolas Aide, Dennis Vriens, Lisa S. Arkes, Cornelis H. Slump, Ronald Boellaard, Jelle J. Goeman, Christophe M. Deroose, Jean-Pascal Machiels, Lisa F. Licitra, Renaud Lhommel, Alessandra Alessi, Erwin Woff, Karolien Goffin, Christophe Le Tourneau, Jocelyn Gal, Stephane Temam, Jean-Pierre Delord, Floris H. P. van Velden, Lioe-Fee de Geus-Oei
Summary: The study aimed to build and externally validate an [F-18]FDG PET radiomic model for predicting overall survival in patients with head and neck squamous cell carcinoma. Two multicentre datasets were used to train and validate the model, which included patients treated with preoperative afatinib. The radiomic model outperformed the clinical model in predicting overall survival.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Valentina Ambrosini, Sofia Carrilho Vaz, Niloefar Ahmadi Bidakhvidi, Marion Chanchou, Matthijs C. F. Cysouw, Francesca Serani, Conrad-Amadeus Voltin, Francoise Kraeber-Bodere, Christophe M. Deroose, Lioe-Fee De Geus-Oei, Matthias Eiber, Gopinath Gnanasegaran, Martin Gotthardt, Carsten Kobe, Mark W. Konijnenberg, Cristina Nanni, Daniela E. Oprea Lager, Kambiz Rahbar, David Taieb, Felix M. Mottaghy, Karolien Goffin, Ken Herrmann
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
H. Leupe, E. Pauwels, T. Vandamme, B. Van den Broeck, W. Lybaert, J. Dekervel, J. Jaekers, F. Cleeren, J. Hofland, A. Brouwers, M. Koole, G. Bormans, E. Van Cutsem, K. Geboes, C. Verslype, S. Stroobants, C. M. Deroose
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
W. Claeys, W. Deckers, V. Nuttens, C. Deroose, K. Goffin, K. Baete, M. Koole
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Meeting Abstract
Endocrinology & Metabolism
Bidakhvidi N. Ahmadi, G. Lens, V. Vandecaveye, S. Grauwels, W. Deckers, J. Dekervel, C. Verslype, E. van Cutsem, M. Koole, K. Goffin, K. van Laere, C. M. Deroose
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Review
Oncology
David Pasquier, Luc Bidaut, Daniela Elena Oprea-Lager, Nandita M. Desouza, David Krug, Laurence Collette, Wolfgang Kunz, Yazid Belkacemi, Maria Grazia Bau, Caroline Caramella, Lioe-Fee De Geus-Oei, Alex De Caluwe, Christophe Deroose, Olivier Gheysens, Ken Herrmann, Isabelle Kindts, Michalis Kontos, Sherko Kuemmel, Barbro Linderholm, Egesta Lopci, Icro Meattini, Ann Smeets, Orit Kaidar-Person, Philip Poortmans, Pelagia Tsoutsou, Nawale Hajjaji, Nicola Russell, Elzbieta Senkus, Jean-Noel Talbot, Lale Umutlu, Vincent Vandecaveye, Joost J. C. Verhoeff, Willemien Menke-van der Houven van Oordt, Helle D. Zacho, Fatima Cardoso, Laure Fournier, Frederieke Van Duijnhoven, Frederic E. Lecouvet
Summary: Breast cancer is the most common cause of cancer death among women, but the current definitions and clinical trials of oligometastatic breast cancer do not consider the histological and molecular heterogeneity of breast cancer. A Delphi questionnaire developed by 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups provides recommendations for the definition, optimal diagnostic pathways, and clinical trials of oligometastatic breast cancer. The main recommendations include introducing modern imaging methods for early diagnosis and conducting prospective trials considering the complexity of breast cancer.